Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases.
COVID-19
SARS-CoV-2
case reports
new coronavirus
polymerase chain reaction
positive
repeated
systematic review
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
19 03 2021
19 03 2021
Historique:
received:
28
02
2021
revised:
15
03
2021
accepted:
16
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
Repeated positivity and reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is a significant concern. Our study aimed to evaluate the clinical significance of repeatedly positive testing after coronavirus disease 2019 (COVID-19) recovery. We performed a systematic literature search following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. With available individual patient data reporting on repeatedly SARS-CoV-2 positive (RSP) patients, case reports, and case series were included in this analysis. We performed a descriptive analysis of baseline characteristics of repeatedly positive cases. We assessed the cases according to the length of their polymerase chain reaction (PCR) negative interval between the two episodes. Risk factors for the severity of second episodes were evaluated. Overall, we included 123 patients with repeated positivity from 56 publications, with a mean repeated positivity length of 47.8 ± 29.9 days. Younger patients were predominant in the delayed (>90 days) recurrent positive group. Furthermore, comparing patients with RSP intervals of below 60 and above 60 days, we found that a more severe disease course can be expected if the repeated positivity interval is shorter. Severe and critical disease courses might predict future repeatedly positive severe and critical COVID-19 episodes. In conclusion, our results show that the second episode of SARS-CoV-2 positivity is more severe if it happens within 60 days after the first positive PCR. On the other hand, the second episode's severity correlates with the first.
Identifiants
pubmed: 33808867
pii: v13030512
doi: 10.3390/v13030512
pmc: PMC8003803
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Regional Development Fund
ID : GINOP-2.3.4-15-2020-00010
Références
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Sci Rep. 2020 Jul 17;10(1):11887
pubmed: 32681141
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
EBioMedicine. 2020 Sep;59:102960
pubmed: 32853988
J Med Case Rep. 2013 Sep 10;7:223
pubmed: 24228906
Clin Infect Dis. 2021 Nov 2;73(9):e2841-e2842
pubmed: 33043962
Lancet Infect Dis. 2021 Jan;21(1):3-5
pubmed: 33058796
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Emerg Microbes Infect. 2020 Dec;9(1):2571-2577
pubmed: 33196399
Protein Cell. 2021 Mar;12(3):230-235
pubmed: 32978728
Clin Infect Dis. 2021 Jul 15;73(2):354-356
pubmed: 32887979
Vaccines (Basel). 2022 Dec 20;11(1):
pubmed: 36679852
Cureus. 2020 Sep 5;12(9):e10264
pubmed: 33042702
Radiology. 2020 Aug;296(2):E15-E25
pubmed: 32083985
J Med Virol. 2020 Oct;92(10):1902-1914
pubmed: 32293716
Rev Med Virol. 2021 Mar;31(2):e2162
pubmed: 32964627
Thorax. 2021 Jan;76(1):61-63
pubmed: 32963115
Allergy. 2020 Oct;75(10):2445-2476
pubmed: 32584441
Clin Microbiol Infect. 2021 Mar;27(3):315-318
pubmed: 33285276
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):13-25
pubmed: 33113040
Int J Infect Dis. 2020 Jul;96:288-290
pubmed: 32437933
Cell Death Discov. 2020 Dec 2;6(1):138
pubmed: 33298894
J Am Geriatr Soc. 2020 Oct;68(10):2179-2183
pubmed: 32638347
J Infect. 2021 Apr;82(4):84-123
pubmed: 33207255
J Med Virol. 2021 Mar;93(3):1599-1604
pubmed: 32897549
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):1-12
pubmed: 33037944